English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 12 May 2021, 12:17 JST
Share:
    

Source: Mitsubishi Heavy Industries, Ltd.
MHI Thermal Systems Confirms Effectiveness of Air Purification Filtering Technology for Removal and Inactivation of SARS-CoV-2

TOKYO, May 12, 2021 - (JCN Newswire) - Mitsubishi Heavy Industries Thermal Systems, Ltd. (MHI Thermal Systems), a part of Mitsubishi Heavy Industries (MHI) Group, has confirmed that the air purification technology it has developed is effective for removal and inactivation of the novel coronavirus (SARS-CoV-2). This technology suppresses pollen and other allergens collected in the filter utilizing the power of enzymes and urea. MHI Thermal Systems had previously verified that a liquid enzyme-urea formulation had the capability to remove and inactivate SARS-CoV-2 (announced in February this year) and has now completed effectiveness verification with a test air filter.

A demonstration test(1) for this technology was conducted by Japan Textile Products Quality and Technology Center (Q-TEC). Specifically, filtering media in MHI Thermal Systems' air purification filters was inoculated with a viral fluid containing SARS-CoV-2, and left to rest in an incubator at 35degC for one hour. The stirred material was then collected, and the viral titer determined through plaque assay(2) (plaque-forming units (PFU)). Compared to the control sample of viral fluid containing SARS-CoV-2 (left for one hour), the rate of inactivation for the filtering media in the air purification filter was 99.998%, confirming that in one hour of reaction time, the SARS-CoV-2 had been rendered nearly completely inactive.

Research to remove or inactivate viruses in areas where indoor air conditioning systems are applicable contributes to efforts to counter viruses in indoor spaces, and is a pressing social issue. Going forward, MHI Thermal Systems will continue to conduct research in this field to develop antibacterial and antiviral technologies, to contribute to the realization of a society in which people can live with peace of mind.

(1) A demonstration test is conducted in a test environment, rather than with real equipment under actual usage conditions.
(2) Plaque assay is a method to determine the viral load using degeneration of cells infected with a virus, by measuring the number of holes that form as the infected cells break down and peel off.

About MHI Group

Mitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, logistics & infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on www.spectra.mhi.com.

Topic: Press release summary
Source: Mitsubishi Heavy Industries, Ltd.

Sectors: MedTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 
Mitsubishi Heavy Industries, Ltd. Links

http://www.mhi.com

https://www.mhi.com/rss/

https://www.facebook.com/mhi.ltd/

https://twitter.com/MHI_Group

https://www.youtube.com/user/DiscoverMHI

https://www.linkedin.com/company/mitsubishi-heavy-industries/

Mitsubishi Heavy Industries, Ltd. Related News
Wednesday, 8 May 2024, 14:27 JST
Mitsubishi Heavy Industries Increases Dividends on Back of Historically High FY2023 Results, Releases FY2024 Guidance
Tuesday, 7 May 2024, 13:49 JST
MHI Agrees to Collaborate with Chiyoda Corporation for Licensing of CO2 Capture Technologies
Monday, 29 April 2024, 18:49 JST
SPARX Group Establishes Space Frontiers Second Fund
Monday, 29 April 2024, 18:00 JST
MHI Establishes Local Subsidiary "Mitsubishi Heavy Industries Vietnam"
2024年4月26日 14時00分 JST
スパークス・グループによる「宇宙フロンティア2号ファンド」の設立について
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575